REVIVA PHARMACEUTICALS HOLDINGS, INC.(RVPH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RVPH Stock Analysis & AI Quality Score
AI stock analysis and institutional research for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH), a Healthcare sector company. RVPH is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), REVIVA PHARMACEUTICALS HOLDINGS, INC. reports net income of $-3.2M, free cash flow of $-3.8M. Top institutional holders of RVPH by reported 13-F value include MILLENNIUM MANAGEMENT, HIGHBRIDGE CAPITAL MANAGEMENT, JPMORGAN CHASE & CO, based on the most recent SEC filings. RVPH trades on the Nasdaq exchange and files with the SEC under CIK 1742927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RVPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REVIVA PHARMACEUTICALS HOLDINGS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-3.2M
Free Cash Flow
Q1 2026
$-3.8M
D/E Ratio
Q1 2026
0.01
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+33.6% YoYOperating Income
+34.4% YoYTotal Assets
+2.7% YoYTotal Debt
-11.2% YoYOp. Cash Flow
+26.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 |
|---|---|---|---|---|---|
| Net Income | $-19.9M +33.6% | $-29.9M +23.8% | $-39.3M -38.9% | $-28.3M -3237.3% | $-846.8K |
| Operating Income | $-20.2M +34.4% | $-30.8M +22.0% | $-39.5M -39.9% | $-28.2M -7390.5% | $-376.9K |
| Total Assets | $15.9M +2.7% | $15.5M -34.6% | $23.7M +25.2% | $18.9M +727733.7% | $2.6K |
| Total Debt | $406.9K -11.2% | $458.2K | $0.00 | $0.00 | — |
| Operating Cash Flow | $-24.6M +26.7% | $-33.5M -18.4% | $-28.3M -49.4% | $-19.0M -8579.8% | $-218.4K |
AI Insight: RVPH Ratio Trends
Reviva remains deeply unprofitable with negative returns across all metrics; ROE improved from -155.8% in Q4 2025 to -73.3% in Q1 2026 but company is still destroying shareholder value.
• ROE improved from -155.8% in Q4 2025 to -73.3% in Q1 2026; ROA similarly improved from -84.6% to -54.3%.
• Debt-to-equity ratio near zero (0.01 in TTM and Q1 2026), indicating minimal leverage and low financial risk.
• TTM ROIC stands at -95.8% with negative ROA of -70.6%, reflecting sustained operating losses.
⚠ Sequential ROE decline from -73.3% in Q1 2026 to TTM -95.3% suggests deterioration masked by year-ago comparisons.
⚠ Operating margins and net profit margins unavailable; unable to assess expense control or path to profitability.
Get alerted when RVPH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for REVIVA PHARMACEUTICALS HOLDINGS, INC. including:
Top Institutional Holders of RVPH
MILLENNIUM MANAGEMENT LLC
$579.3K793,948 shHIGHBRIDGE CAPITAL MANAGEMENT LLC
$556.2K762,236 shJPMORGAN CHASE & CO
$556.2K762,236 shARMISTICE CAPITAL, LLC
$432.0K592,079 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$366.7K502,300 shVANGUARD CAPITAL MANAGEMENT LLC
$85.8K117,568 shWarberg Asset Management LLC
$66.2K90,772 shGEODE CAPITAL MANAGEMENT, LLC
$53.3K72,992 shRENAISSANCE TECHNOLOGIES LLC
$31.4K43,002 shVANGUARD FIDUCIARY TRUST CO
$23.1K31,598 sh
| Fund | Value | Shares |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | $579.3K | 793,948 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $556.2K | 762,236 |
| JPMORGAN CHASE & CO | $556.2K | 762,236 |
| ARMISTICE CAPITAL, LLC | $432.0K | 592,079 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $366.7K | 502,300 |
| VANGUARD CAPITAL MANAGEMENT LLC | $85.8K | 117,568 |
| Warberg Asset Management LLC | $66.2K | 90,772 |
| GEODE CAPITAL MANAGEMENT, LLC | $53.3K | 72,992 |
| RENAISSANCE TECHNOLOGIES LLC | $31.4K | 43,002 |
| VANGUARD FIDUCIARY TRUST CO | $23.1K | 31,598 |
More Healthcare Companies
View all Healthcare →Put RVPH on your watchlist
Track score changes the day REVIVA PHARMACEUTICALS HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RVPH a good stock to buy?
13F Pro's AI-powered analysis of REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RVPH are available on the RVPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RVPH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RVPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REVIVA PHARMACEUTICALS HOLDINGS, INC.'s investment landscape.